DOCSLIB.ORG

By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie Fellows Royal Society of Canada Fellows Killam Fellows 0 20 40 60 801 00 Percentage * Current Foreign Honorary Members only ** The National Academies consists of: Members or Foreign Asssociate Members of the Institute of Medicine, National Academy of Engineering and National Academy of Sciences *** As of August 2009 **** Federal Granting Councils’ Highest Awards: NSERC: Gerhard Hertzberg Canada Gold Medal for Science and Engineering; CIHR: Michael Smith Prize in Health Research; SSHRC: Gold Medal for Achievement in Research The following honours consist of data up to 2008 only: Federal Granting Councils, National Academies and Steacie Prize BY THE NUMBERS 2 RERESEARCH FUNDING FEDERAL FUNDINGDINNG U of T’s research funding has been increasing steadily over the past decade. U of T consistently leads all other Canadian universities in investment from federal granting agencies. Research Funds Awarded (1998-99 to 2007-08) U of T including partner hospitals Federal Granting Council Funding to G13 Universities (2008-09) 1000 U TORONTO 800 UBC McGill U U Montréal 600 U Alberta U Laval $ Million 400 McMaster U U Ottawa 200 U Calgary U Western Ont. SSHRC U Waterloo 0 NSERC Queenʼs U 1998-99 1999-00 2000-01 2001-02 2002-03 2003-04 2004-05 2005-06 2006-07 2007-08 Dalhousie U CIHR All Sources Federal Granting Councils 0 50 100 150 200 250 300 $ Millions Federal Granting Councils includes funding for Canada Research Chairs (SSHRC, NSERC and CIHR) Data Sources: Federal Granting Councils Excludes Networks of Centres of Excellence, Canada Research Chairs, Indirect Costs Research funding at U of T comes from a variety of sources, in particular and funding for the Canadian Microelectronics Corporation the federal and provincial governments. Affiliates and partner hospitals counted with each university Research Funds Awarded by Sector (2007-08) Canada Research Chairs at G13 Universities (2008-09) Total: $850M Federal Granting Councils U TORONTO 35% UBC Inter-Institutional Collaboration McGill U 8% U Montréal U Alberta U Laval U Calgary Not-For-Profit Other Federal U Ottawa 15% 16% McMaster U U Western Ont. U Waterloo International Queenʼs U 3% Government of Ontario Dalhousie U 13% Corporations 0 50 100 150 200 250 Other Government Number of Chairs allocated 9% 1% Notes: For U of T and partner hospitals Data Source: CRC website, updated January 2009 Includes overhead and indirect costs Affiliates and partner hospitals counted with each university 3 UNIVERSITY OF TORONTO BY THE NUMBERS 4 FEFEDERAL FUNDING PROVINCIAL FUNDINGDINNG U of T consistently leads all other Canadian universities in U of T leads all Ontario universities in funding from investment from federal granting agencies. the Ministry of Research and Innovation. Canada Foundation for Innovation Funding Ontario Ministry of Research and Innovation Funding to G13 Universities Top 10 universities U TORONTO U TORONTO UBC McGill U U Western Ont. U Montréal Queen's U U Alberta McMaster U McMaster U U Laval U Waterloo U Western Ont. U Ottawa U Ottawa U Calgary U Guelph U Waterloo York U Queenʼs U Dalhousie U Carleton U 0 100 200 300 400 500 600 700 800 Laurentian U $ Millions 0 50 100 150 200 250 300 $ Millions Limited to main competitive programs (funding since inception) Limited to universities (includes partner hospitals and affiliates) Data Sources: Research Infrastructure Award – up to November 27, 2008 Ontario Research Fund Research Excellence Award – Rounds 1 to 3 (MRI web site September 10, 2009) Early Researcher Award estimated to be $140,000 per award; Rounds 1 to 5 (MRI web site September 3, 2009) Post-Doctoral Fellowship Allocations – Rounds 1 to 3, valued at $50,000 each (MRI, September 4, 2009) Data Source: CFI website, June 18, 2009 (funding since inception) Ontario Research Chair – Round 1 (MRI web site November 23, 2008) Affiliates and partner hospitals counted with each university Premier’s Discovery Award Round 1, 2 & 3 (MRI web site September 3, 2009) Premier’s Summit Award Round 1, 2 & 3 (MRI web site September 3, 2009) 5 UNIVERSITY OF TORONTO BY THE NUMBERS 6 ININDUSTRIN Y FUNDING INNOVATIONS U of T is among Canada’s leaders in U of T is among North America’s leaders industry-sponsored research. in new invention disclosures. Industry Funding to G13 Universities (2007-08) Invention Disclosures (2005-07) U.S. & Canadian universities U TORONTO Caltech U Montréal U Wisconsin (Madison) U Alberta Georgia Inst Tech Queenʼs U MIT UBC U Illinois (Urbana & Chicago) U Laval U TORONTO U Calgary Stanford U Western Ont. U Pennsylvania Dalhousie U U Washington U Ottawa U Michigan McGill U U Florida U Waterloo SUNY 0 10 20 30 40 50 60 70 80 Purdue $ Millions Johns Hopkins Cornell U Minnesota U Colorado Harvard Indiana U U Guelph 0 500 1,000 1,500 2,000 Number of new disclosures Data Source: CAUBO 2007-08 Data Source: AUTM Survey FY 2007, 2006 and 2005 Toronto data corrected for one-year lag in reporting from partner hospitals Note: University of Toronto includes the following affiliated hospitals: Bloorview McMaster not shown due to comparability issues Kids Rehab, Centre for Addiction and Mental Health, Hospital for Sick Children, Sunnybrook Health Sciences Centre and University Health Network University of California, only available as a system aggregate, is not shown 7 UNIVERSITY OF TORONTO BY THE NUMBERS 8 INNOVININ ATIONS IMPACT U of T is among North America’s leaders in U of T is one of the leading institutions in North America creating spin-off companies. for publications and citations. Rankings on Publications and Citations (2004-08) G13 (Canada) AAU† Public AAU† All New Spin-off Companies (2005-07) Publications Citations Publications Citations Publications Citations U.S. & Canadian universities All Fields* 1 1 1 3 2 6 All Sciences* 1 1 1 3 2 6 Health & Life Sciences* 1 1 1 1 2 3 Paediatrics 1 1 1 1 2 2 MIT Paediatrics & Pharmacy 1 1 1 1 2 2 U Utah Oncology 1 1 1 1 2 3 1 1 1 2 2 6 U Florida Genetics & Heredity Engineering & Materials Science** 1 1 6 8 7 12 U Colorado Environmental Engineering 1 1 2 1 2 1 Purdue Biomedical Engineering 1 1 1 2 2 5 SUNY Physics, Atomic, Molecular & Chemical 1 1 3 4 7 8 1 1 3 4 8 10 Georgia Inst Tech Optics Physical Chemistry 1 1 4 8 6 11 Carnegie Mellon U Social Sciences** 1 1 3 5 4 8 U Washington Behavioural Sciences 1 1 1 2 2 5 U Illinois (Urbana & Chicago) Criminology & Penology 1 1 2 4 2 4 U Michigan Caltech Data Source: Northwestern U Thomson Reuters, University Science Indicators (U.S. and Canada), Deluxe Edition, 2008, unless otherwise indicated by *(Standard and Deluxe Editions, U of T groupings) or **(Standard Edition) U Pittsburgh † Association of American Universities supplemented with the Canadian G13 institutions and the University of California at U TORONTO San Francisco. Data not available for Texas A&M College Station U New Mexico U Kentucky U Wisconsin (Madison) U Maryland (College Park) Harvard World University Rankings 0 10 20 30 40 50 60 70 In the 2009 Times Higher Education-QS World University Rankings, U of T was Number of companies ranked by academic peers globally as one of the leading institutions in all fi elds: • 8th in the world in Engineering and Information Technology • th Data Source: AUTM Survey FY 2007, 2006 and 2005 11 in the world in Life Sciences and Biomedicine th Note: University of Toronto includes the following affiliated hospitals: Bloorview Kids • 11 in the world in Arts and Humanities Rehab, Centre for Addiction and Mental Health, Hospital for Sick Children, Sunnybrook • 14th in the world in Natural Sciences Health Sciences Centre and University Health Network University of California, only available as a system aggregate, is not shown • 15th in the world in Social Sciences 9 UNIVERSITY OF TORONTO BY THE NUMBERS 10 AWARDS AND HONOURS Lewis E. Kay, Molecular Genetics, Biochemistry, McLaughlin Medal Gerhard Herzberg Gold Medal for Selected Awards and Honours in the past three years. Chemistry John R.G. Challis, Physiology Science and Engineering, Natural Eugenia Kumacheva, Chemistry Michael Tyers, Molecular Genetics Sciences and Engineering Research English Council of Canada Aurora Prize, Social Sciences and Locke Rowe, Ecology & Evolutionary Biology James Smith, Chemical Engineering & Ian Lancashire, OISE/UT Miroslaw Romanowski Medal J.
Load more

Recommended publications
  • The Cambridge Companion to Canadian Literature Edited by Eva-Marie Kröller Frontmatter More Information
    Cambridge University Press 978-1-107-15962-4 — The Cambridge Companion to Canadian Literature Edited by Eva-Marie Kröller Frontmatter More Information The Cambridge Companion to Canadian Literature This fully revised second edition of The Cambridge Companion to Canadian Literature offers a comprehensive introduction to major writers, genres, and topics. For this edition several chapters have been completely re-written to relect major developments in Canadian literature since 2004. Surveys of ic- tion, drama, and poetry are complemented by chapters on Aboriginal writ- ing, autobiography, literary criticism, writing by women, and the emergence of urban writing. Areas of research that have expanded since the irst edition include environmental concerns and questions of sexuality which are freshly explored across several different chapters. A substantial chapter on franco- phone writing is included. Authors such as Margaret Atwood, noted for her experiments in multiple literary genres, are given full consideration, as is the work of authors who have achieved major recognition, such as Alice Munro, recipient of the Nobel Prize for literature. Eva-Marie Kröller edited the Cambridge Companion to Canadian Literature (irst edn., 2004) and, with Coral Ann Howells, the Cambridge History of Canadian Literature (2009). She has published widely on travel writing and cultural semiotics, and won a Killam Research Prize as well as the Distin- guished Editor Award of the Council of Editors of Learned Journals for her work as editor of the journal Canadian
    [Show full text]
  • The Early History of Medical Genetics in Canada William Leeming OCAD University [email protected]
    OCAD University Open Research Repository Faculty of Liberal Arts & Sciences and School of Interdisciplinary Studies 2004 The Early History of Medical Genetics in Canada William Leeming OCAD University [email protected] © Oxford University Press. This is the author's version of the work. It is posted here for your personal use. Not for redistribution. Original source at DOI: 10.1093/shm/17.3.481. Recommended citation: Leeming, W. “The Early History of Medical Genetics in Canada.” Social History of Medicine 17.3 (2004): 481–500. Web. Leeming, W. (2004). The early history of medical genetics in Canada. Social History of Medicine, 17(3), 481-500. Pre-Publication Draft The Early History of Medical Genetics in Canada Abstract: This article shows that the intellectual and specialist movements that supported the growth of medical genetics in Canada between 1947 and 1990 were emergent phenomena, created, split, and reattached to different groups of actors, and reconfigured numerous times over the course of four decades. In each instance, new kinds of working relationships appeared; sets of diverse actors in local university- hospital settings coalesced into a new collectivity; and, as a collectivity, actors defined and/or redefined occupational roles and work rules. In its beginnings, medical genetics appears to be the object of a serious institutional manoeuver: a movement in support of the creation of examining and teaching positions in human genetics in North American medical schools. With time, the institutionalization of ‘medical genetics’ took hold, spurred on by changes in the rate and direction of service delivery associated with genetic consultation and laboratory services in clinical settings.
    [Show full text]
  • Which Canadian Charities Had the Largest Assets in 2014?
    www.canadiancharitylaw.ca Which Canadian charities had the largest assets in 2014? By Mark Blumberg (March 23, 2016) We recently reviewed the T3010 information for 2014. It covers about 84,370 of the 86,000 registered charities that have so far filed their return and that have been entered into the CRA’s database. Canadian registered charities are currently required to disclose on the T3010 their assets. The total assets of all the 84,370 registered charities were about $373,050,327,255.00. Below we have a table of Canadian charities and how much they spent as reported for the 2014 fiscal year. Thank you to Celeste Bonas, an intern at Blumbergs, for helping with this project. The Sean Blumberg Transparency Project is in memory of my youngest brother Sean Blumberg. Sean was a sweet, kind person, a great brother who helped me on a number of occasions with many tasks including the time consuming and arduous task of reviewing T3010 databases and making them into something useful. As part of the Sean Blumberg Transparency Project, Blumbergs has been releasing information on the Canadian charity sector to provide a better understanding of the size, scope, complexity and challenges of the sector. Please review my caveats at the end about the reliability and usage of T3010 information. 1 www.canadiancharitylaw.ca List of Canadian charities with the largest assets in 2014 Line 4200 Name of Canadian Registered Charity largest assets 1. ALBERTA HEALTH SERVICES $9,984,222,000.00 2. THE MASTERCARD FOUNDATION $9,579,790,532.00 3. THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO $7,681,040,000.00 4.
    [Show full text]
  • 2015 Annual Report
    1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................. 2 HISTORY OF THE GAIRDNER FOUNDATION .................................................................................... 3 MISSION ...................................................................................................................................................... 3 NATIONAL AND STUDENT OUTREACH PROGRAMS ....................................................................... 4 MESSAGE FROM THE CHAIR ............................................................................................................... 5 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ......................................................... 6 2015 YEAR IN REVIEW ............................................................................................................................. 7 REPORT ON 2015 OBJECTIVES ............................................................................................................ 14 THE YEAR AHEAD: OBJECTIVES FOR 2016 ..................................................................................... 16 THE GAIRDNER FOUNDATION VALUES OUR 2015 SPONSORS ................................................... 18 GOVERNANCE ......................................................................................................................................... 20 MEDICAL REVIEW PANEL 2015 .........................................................................................................
    [Show full text]
  • C:\Users\Carolanne\Documents
    If you are having trouble viewing this email, please select here. January 25, 2012 Vol. 20, No. 10 From Banting and Best's discovery of insulin, to Till and McCullough's stem cell breakthrough, the University of Toronto Faculty of Medicine has an incredible legacy of visionary, ground-breaking research. Medical advances traced back to our labs have made countless real-world improvements in patient therapies and care. Together with our TAHSN partners, we truly are a national and international research powerhouse. Ranked 4th for research in Clinical Medicine among World Universities by the Higher Education Council of Taiwan, we are home to 125 Canada Research Chairs, 2 Canada Excellence in Research Chairs, and over 2000 masters and doctoral students who are critical to our research capacity. On January 24, our medical students presented 170 research posters and several oral presentations at their annual research day - a remarkable demonstration of the interest and engagement of our students in scientific enquiry. With the fundamentals in place, there is a tremendous opportunity in Canada to lead the future development of the health research agenda worldwide. But it is not sufficient to do what we have always done. Leadership in the health research of tomorrow will require us to adapt to new realities - where leading-edge investigation takes place across systems and disciplines, and where data can be collected and shared in ways we have not previously envisioned and on a scale we have never before seen. We must create new structures that break down old silos and allow the broad sharing of knowledge.
    [Show full text]
  • Breast Density What Are the Implications for Cancer Screening?
    2018 ISSUE 2 Breast Density What are the implications for cancer screening? Key Concepts Fever in children returning from travel Choose Wisely Deciding on tests and treatments using the evidence base is Proud to celebrate 10 YEARS in Canada 42 million patients treated in clinical practice worldwide across all indications1 Thank you for your partnership over the last 10 years. We look forward to many more. Xarelto® is indicated for treatment of venous thromboembolic events For the treatment of VTE, Xarelto® is not recommended as an alternative (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention to unfractionated heparin in patients with acute pulmonary embolus of recurrent DVT and PE. who are haemodynamically unstable, or who may receive thrombolysis or pulmonary embolectomy, since the safety and effi cacy of Xarelto® Xarelto® is indicated for the prevention of stroke and systemic have not been established in these clinical situations. embolism in patients with atrial fi brillation, in whom anticoagulation is appropriate. Xarelto® is not recommended for use in children less than 18 years of age. Xarelto® is indicated for the prevention of venous thromboembolic Consult the Xarelto® Product Monograph at http://bayer.ca/xarelto events (VTE) in patients who have undergone elective total hip for contraindications, warnings, precautions, adverse reactions, replacement (THR) or total knee replacement (TKR) surgery. interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-265-7382. References: 1. Bayer data on fi le. 2. Xarelto® (rivaroxaban tablet) Product Monograph. Bayer Inc. May 9, 2018. ® TM see www.bayer.ca/tm-mc © 2018, Bayer Inc.
    [Show full text]
  • Radiation Medicine Program
    Radiation Medicine Program ANNUAL 2020 REPORT 2021 VALUES MISSION Innovation Advance exemplary radiation Excellence medicine through patient Collaboration care, research & education Accountability in partnership with CONTENTS Integrity our patients & community 4 A Message from the Chief 6 Program Overview 7 2020: The Year in Numbers 8 Strategic Roadmap to 2026 VISION 10 Clinical Care CURE EVOLVE 15 Quality & Safety Predictive Health & Precision Radiation Medicine. Advanced Particle Adaptive Radiotherapy Therapy & Theranostics 18 Education Personalized Care. 21 Research Global Impact. 26 Team RMP COMFORT & CONNECT Systems to Maximize CONFIDENCE Innovation & Wellbeing Technology-enabled Patient Experience Transformation A MESSAGE FROM THE CHIEF The Radiation Medicine Program (RMP) at the Princess Margaret Cancer Centre is committed to delivering the highest standard of patient care. Over the RMP’s innovative education programs continue to thrive and attract a diverse group of national and international attendees. Our award-winning Accelerated past year, our dynamic multidisciplinary team of radiation oncologists, medical physicists, radiation therapists, administrators, and support staff have worked Education Program (AEP) demonstrated extraordinary resourcefulness this past year, standing strong amidst the pandemic, and continuing to provide top- together to advance our vision of “Precision Radiation Medicine. Personalized Care. Global Impact.” RMP continues to uphold our foundational values of level education to a broad spectrum of learners.
    [Show full text]
  • 2015 Annual Summary Corporate Plan
    The Gairdner Foundation Corporate Plan 2015 1 TABLE OF CONTENTS PAGE Section I About the Gairdner Foundation 2 Objectives and Achievements to Date 5 Benefits 7 Section II Performance Results for 2014 Activities 7-8 Detailed 2014 Evaluations 9-10 Planned Activities and Anticipated Results 2015 11 Section III Financial Summary 12 Planned Receipts and Disbursements 2015 13-15 Section IV Risk Management 16 Section V Performance Monitoring 17-19 2 THE GAIRDNER FOUNDATION CORPORATE PLAN EXECUTIVE SUMMARY HISTORY The Gairdner Foundation was created by James A. Gairdner to recognize and reward the achievements of medical researchers whose work “contributes significantly to improving the quality of human life”. The Foundation is a Canadian organization that has never lost sight of its primary mission – the recognition of scientists it deemed to have made the most important breakthrough discoveries in biomedical science. It’s recipients are responsible for the discovery of the structure of DNA, the eradication of smallpox, CT scans, MRI machines, the human genome, the cure for ulcers, and the vaccine against HPV, to name a few. Since the first awards were granted in 1959, the Canada Gairdner Awards have become Canada's foremost international award- and one of the most prestigious awards in medical science. Our track record of consistent high quality adjudication and selection by the independent adjudication committees have resulted in global recognition and esteem. The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. During 2013, the Foundation was continued as a federal corporation under the Canada Not-For-Profit Corporations Act.
    [Show full text]
  • Health Matters Fall 2017
    THE OTTAWA VALLEY’S HEALTH MAGAZINE HealthMattersFREE! FALL 2017 Eating With A Happy Heart: Advice from the authors of Looneyspooons Local Canadian Experts Health Feature Facts Section: FOOD! Kids Lunch Church Suppers Hacks Around The County! Saving Silas: Meet a little boy who was The Food born with the will to live Crossword In honour of Canada’s 150th, we Canada 150 are trying to attract 150 aircraft to fly-in to the airport on one day! FLY-IN Come Join Us! Thi s goi is g n to be a very o c ay. ol d September 23rd | 10am-3pm This is a FREE event to attend. Pembroke & Area Lunch is available for purchase. AIRPORTT Plus: Ry-J’s, Aircraft Simulator, 49 Years in Aviation. and Canadian Forces aircraft on display! Easy parking in the Expo 150 field across from the airfield. Seating available at the airfield. Meet local and visiting pilots who are flying-in on this special day. 176 Len Hopkins Drive, Petawawa. Visit www.flycyta.ca/Canada150 or www.facebook.com/flycyta. Pembroke & Area AIRPORTT 49 Years in Aviation. FROM THE PUBLISHER FALL 2017 A Letter From Audrey Reader’s handwritten letter says it best about the Health Matters vision as we complete our fifth year After our last issue, I received a handwritten Ottawa Valley, even lifetime residents are letter in the mail from a woman named Audrey. unaware of! You do an excellent job of It was so compelling that I realized I could not bringing them to light, so more residents can do a better job than she did for the Publisher’s use them to make their lives better.
    [Show full text]
  • Maud Menten, a Physician and Biochemist
    Maud Menten Canadian medical researcher Maud Menten (1879-1960) has been called the "grandmother of biochemistry," a "radical feminist 1920s flapper," and a "petite dynamo." Not only was she an author of Michaelis-Menten equation for enzyme kinetics (like the plot in indigo in my portrait), she invented the azo-dye coupling for alkaline phosphatase, the first example of enzyme histochemistry, still used in histochemistry imaging of tissues today (which inspired the histology background of the portrait), and she also performed the first electrophoretic separation of blood haemoglobin in 1944! Born in Port Lambton, Ontario, she studied at the University of Toronto, earning her bachelor's in 1904, and then graduated from medical school (M.B., bachelor's of medicine) in 1907. She published her first paper with Archibald Macallum, the Professor of Physiology at U of T (who went on to set up the National Research Council of Canada), on the distribution of chloride ions in nerve cells in 1906. She worked a year at the Rockefeller Institute in New York, where along with Simon Flexner, first director of the Institute, she co-authored a book on radium bromide and cancer, the first publication produced by the Institute - barely 10 years after Marie Curie had discovered radium. She completed the first of two fellowships at Western Reserve University (now Case Western Reserve University), then she earned a doctorate in medical research in 1911 at U of T. She was one of the first Canadian women to earn such an advanced medical degree. She then moved to Berlin (travelling by boat, unfazed by the recent sinking of the Titanic) to work with Leonor Michaelis.
    [Show full text]
  • LORNE PIERCE MEDAL – Royal Society Of
    LORNE PIERCE MEDAL – Royal Society of Canada Nomination Deadline: March 2022 Internal Deadline: TBD Good to know: Nomination is by Fellow of the Royal Society or our President Sponsor: Royal Society of Canada Web Site: https://rsc-src.ca/en/awards-excellence/rsc-medals-awards#Pierce For an achievement in critical or imaginative literature. Awarded: Biennially Next deadline: 2022 The medal was established in 1926 by Lorne Pierce (1890-1961), FRSC, who was Editor of Ryerson Press for forty years and contributed greatly to the development and appreciation of Canadian literature. The medal is awarded for an achievement of special significance and conspicuous merit in imaginative or critical literature written in either English or French (critical literature dealing with Canadian subjects has priority over critical literature of equal merit that does not deal with Canadian subjects). The gold plated silver medal is offered every two years if there is a suitable candidate. In addition to the specific information to be included in the nomination form, a complete nomination also comprises the following items: (1) a letter from the Primary Nominator (2) two letters from co-nominators attesting to their support of the nomination (3) a short citation (max 70 words) (4) a detailed appraisal of the nominee’s scholarship or artistic achievements (max 1200 words) (5) three letters of reference from independent referees and their biographies (6) a Curriculum Vitae (maximum of 20 pages) CONTACT Interested faculty are encouraged to consult with Danelle D'Alvise, Prizes & Awards Manager in the Office of the Vice-President, Research regarding this Medal and for assistance with the nomination process including: writing, editing and proofreading required elements of the nomination package; securing letters of support; and managing the submission process to ensure deadlines are met.
    [Show full text]
  • Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund
    A Pre-Budget Submission to the House of Commons Standing Committee on Finance To Implement the Canadian Stem Cell Strategy By Establishing The Till & McCulloch Medicines of Tomorrow Innovation Fund James Price President & CEO Canadian Stem Cell Foundation February 9, 2016 EXECUTIVE SUMMARY Stem cells represent the biggest innovation in medicine of the last half century. These cells have the power to cure many diseases for which current medical practice can only provide symptomatic relief and chronic care – a reality that is straining health care systems in Canada and in countries around the globe. Stem cells are a hallmark of Canadian innovation. They were first discovered in Canada and Canada is one of the top three countries in stem cell R&D, with our scientists ranking among the best in the world. Recent investments, such as the Government’s $20-million commitment to establish a cell-manufacturing facility in Toronto and the $114-million Medicine By Design grant for the University of Toronto, will help Canada move forward. However, major commitments by competitor jurisdictions – most notably California, with its investment of $3 billion, and Japan, with an investment of $1 billion in stem cells and regenerative medicine -- challenge Canada’s leadership in this sector of the knowledge economy. Moreover, Canada lacks a national plan to succeed in the coming cell therapy and regenerative medicine boom. The Canadian Stem Cell Strategy -- created in consultation with 150 scientists, medical doctors, leaders from major health charities, industry experts, investors and philanthropists – will: • deliver up to 10 new curative therapies within 10 years; • transform health care and ease the strain on the health system; and • attract private investment and generate 12,000 jobs for Canadians.
    [Show full text]